Oxford Spin-Out Lands $300M to Bring Small-Molecule Therapies Closer to Patients

Jan de Vries · 2026-10-16

OMass Therapeutics, a UK biotech company developing small-molecule therapeutics against highly validated target ecosystems, just announced an oversubscribed €275 million ($300 million) Series C round. That's a lot of cash for a company that only launched in 2016. But when you look at the science, it starts to make sense. ### Who's Putting Up the Money? The round was co-led by new investors Bain Capital Life Sciences, Forbion, and Novo Holdings. Additional participation came from Janus Henderson Investors, SV Health Investors, and Jefferson Life Sciences. And every existing investor joined in too—Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, and the University of Oxford. That's a serious syndicate, and it signals real confidence in what OMass is building. "This financing comes at an exciting point in OMass' evolution as we advance OMS1620 into the clinic, with our SLC15A4 inhibitor poised to follow," says Ros Deegan, CEO of OMass Therapeutics. "We have demonstrated the ability of our team and approach to discover and deliver a pipeline of first- and best-in-class programmes in endocrinology and immunology into the clinic. With the backing of an outstanding group of new and existing investors, we are entering our next phase of growth with the resources to translate that progress into a portfolio of clinically differentiated medicines for patients." ### A Wave of European Biotech Funding OMass' round is part of a broader surge in European therapeutics funding this year. In France, Bionyra Pharma secured €143 million ($156 million) for inflammatory disease treatments. Denmark's Breye Therapeutics raised €67.5 million ($74 million) for its oral small-molecule pipeline, also co-led by Novo Holdings. In the UK, Cambridge-based STORM Therapeutics secured €47.5 million ($52 million), Microbiotica raised €42 million ($46 million), Glasgow-based Mironid received €39.9 million ($44 million), and London-based Alchemab Therapeutics secured €29.3 million ($32 million). Add in the Netherlands' Laigo Bio with an additional €5.5 million ($6 million), and these announcements represent roughly €374.7 million ($409 million) in newly reported financing this year—rising to €649.7 million ($710 million) when OMass' round is included. That's a lot of momentum for a sector that was once seen as risky. ### The Science Behind the Hype OMass was founded in 2016 as a spin-out from Professor Dame Carol Robinson's lab at the University of Oxford. The goal? Translate native mass spectrometry research into novel small-molecule therapeutics against historically challenging targets. Its proprietary OdyssION drug discovery platform combines next-generation native mass spectrometry, novel biochemistry techniques, and custom chemistry to interrogate drug targets within their native ecosystems. The result is cell-system fidelity with cell-free precision—a fancy way of saying they can study proteins in their natural environment while still getting the exactness of isolated systems. "OMass leverages an experienced team and a clear vision for building a leading therapeutics company that translates complex biology into differentiated medicines for patients with significant unmet needs," adds Evan Greif, Principal at Bain Capital Life Sciences. "The Company is executing against that vision by advancing OMS1620 and applying its proprietary discovery approach to build a broader pipeline across endocrinology and immunology. We see meaningful potential for OMS1620 to improve the treatment for patients with CAH and look forward to partnering with Ros and the team to support the Company's strategic and patient-first approach." ### What's Next for the Cash? The proceeds will support the advancement of OMass' lead programme, OMS1620—a potential best-in-class MC2 receptor antagonist—through Phase 2 clinical development in congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome. OMS1620 has been designed to increase receptor residency time and maintain a durable response, which could make a real difference for patients. "We are pleased to join a premier investor syndicate supporting OMass as the Company advances its breakthrough programs into the clinic," says Max Klement, Partner, Venture Investments at Novo Holdings. "Each of these candidates has the potential to address substantial unmet patient needs in their respective areas of endocrinology and immunology, and we look forward to the Company's continuing progress." For those tracking EU Inc news and the European startup incorporation scene, this round is a clear signal that deep-tech biotech spin-outs from universities can attract serious capital. The EU Inc proposal, which aims to simplify cross-border incorporation for startups, could make it even easier for companies like OMass to scale across Europe. But for now, OMass is proving that world-class science can still command world-class funding.